TIL Therapy Amplifies the Immune System’s Attack on Melanoma
The recently approved immunotherapy Amtagvi uses a patient’s own immune cells to destroy advanced melanoma.
Home > Patients, Caregivers, and Advocates > Research > TIL Therapy Amplifies the Immune System’s Attack on Melanoma
The recently approved immunotherapy Amtagvi uses a patient’s own immune cells to destroy advanced melanoma.
Your donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now